

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K	A2	(11) International Publication Number: WO 97/10796 (43) International Publication Date: 27 March 1997 (27.03.97)
(21) International Application Number: PCT/IB96/01021 (22) International Filing Date: 30 August 1996 (30.08.96) (30) Priority Data: 60/003,114 1 September 1995 (01.09.95) US (71) Applicant (for all designated States except US): RAMOT- UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. [IL/IL]; 32 Haim Levanon Street, Ramat-Aviv, 61392 Tel-Aviv (IL). (72) Inventor; and (75) Inventor/Applicant (for US only): LAVI, Sara [IL/IL]; 6 Thuat Hameri Street, 55000 Kyriat Ono (IL). (74) Agent: HACKMEY, Michal; A.E. Mulford, 11 Shlom zion Hamalka Street, P.O. Box 544, 91004 Jerusalem (IL).		(81) Designated States: AL, AU, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>

(54) Title: MANIPULATION AND DETECTION OF PROTEIN PHOSPHATASE 2C - PP2C α - EXPRESSION IN TUMOR CELLS
FOR CANCER THERAPY, PREVENTION AND DETECTION

(57) Abstract

A method of detecting cancer in a patient by detecting alteration of activity of the gene coding for human type protein phosphatase 2C (PP2C α and PP2C β) and genetic polymorphisms thereof in a specimen isolated from the patient is disclosed. The invention further provides a method of treating cancer including the steps of first determining the type of cancer and cells expressing the cancer and then preparing a vector which will specifically target the cancer cells and can include regulatory elements to control the expressibility of PP2C α . The vector is then administered to the patient. Alternatively an antisense vector can be prepared.